Lack of CD27 in myeloma delineates different presentation and outcome
Open Access
- 9 December 2005
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 132 (2), 168-170
- https://doi.org/10.1111/j.1365-2141.2005.05849.x
Abstract
CD27 expression was evaluated on normal plasma cells (PC), PC from patients with multiple myeloma (MM) at diagnosis or relapse and on human myeloma cell lines (HMCL). CD27 was expressed by normal PC but was lacking in PC from MM patients at diagnosis (36%) and relapse (47%), and in HMCL (92%). The prognostic impact of CD27 expression was evaluated in 42 patients with de novo MM. Overall survival was 92% at 3 years in CD27+ vs. 50% in CD27– MM (P = 0·017). CD27 expression seems to delineate two important subsets of MM with different presenting features and clinical outcomes.Keywords
This publication has 11 references indexed in Scilit:
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myelomaBlood, 2003
- Clinical and biologic implications of recurrent genomic aberrations in myelomaBlood, 2003
- CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high‐risk diseaseBritish Journal of Haematology, 2003
- Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell developmentBlood, 2003
- A possible role for the loss of CD27–CD70 interaction in myelomagenesisBritish Journal of Haematology, 2003
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyBlood, 2002
- Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentationBlood, 2002
- Interleukin-6 is a growth factor for nonmalignant human plasmablastsBlood, 2001
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996